Though Zynteglo (betibeglogene autotemcel) will be bluebird bio’s first marketed product in the US, the company is ready for a near-term launch of the gene therapy. Chief commercial and operating officer Tom Klima told Scrip after its US Food and Drug Administration approval that Zynteglo treatment centers are being established and payers are coming on board, laying the groundwork for future products.
Bluebird’s Zynteglo Approval Kicks Off Commercial Operations
Beta-Thalassemia Gene Therapy’s List Price Is $2.8m
Bluebird bio’s Tom Klima told Scrip launch preparations are well under way, including negotiations with payers on outcomes-based reimbursement agreements.
